ICARUS IBD

International study of COVID-19 Antibody Response Under Sustained immune suppression in IBD

We aim to determine whether inflammatory bowel disease (IBD) patients on biological therapies are at increased risk of SARS-CoV-2 infection (COVID-19) and to assess prospectively the COVID-19 antibody response. We aim to follow 5000 IBD patients at sixteen infusion centres in nine countries around the world.